Redeye comments on Faron’s announcement of the final outcome of its EUR40m rights issue, which delivered gross proceeds of approximately EUR40.1m and net proceeds of EUR32.8m. The outcome was expected and in line with previously communicated terms, given the fully secured structure. Importantly, the completed financing removes near-term funding uncertainty and secures capital to execute the randomized 90-patient phase II study in frontline HR-MDS, representing the next key value-inflection point.
LÄS MER
